유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cjepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry-ovu bolest - drugi gastrointestinalni trakt i metabolizam, lijekovi, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcije respiratornih sincicijskih virusa - cjepiva - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekcije respiratornih sincicijskih virusa - cjepiva - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. pogledajte odjeljke 4. 2 i 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

보스니아 헤르체고비나 - 크로아티아어 - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

evropa lijek pharma d.o.o. - oksaliplatin - koncentrat za rastvor za infuziju - 5 mg/1 ml - 1 bočica sadrži.5 mg oksaliplatina

보스니아 헤르체고비나 - 크로아티아어 - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

evropa lijek pharma d.o.o. - oksaliplatin - koncentrat za rastvor za infuziju - 5 mg/1 ml - 10 ml koncentrata za rastvor za infuziju sadrži:5 mg oksaliplatina

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

edicta pharm d.o.o., klaićeva 62, zagreb - palonosetronum - otopina za injekciju - 250 mikrograma - urbroj: 1 ml otopine sadrži 50 mikrograma palonozetrona (u obliku palonozetronklorida)

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica - melissae mjestu folii extractum siccum, valerijana extractum siccum hydroalcoholicum, passiflorae herbae extractum siccum - obložena tableta - 112,5 mg + 125 mg + 80 mg - urbroj: svaka obložena tableta sadrži: 112,5 mg ekstrakta (kao suhi ekstrakt) iz melissa officinalis l., folium (matičnjakov list) (4-6:1); ekstrakcijsko otapalo: metanol 30% v/v, 125 mg ekstrakta (kao suhi ekstrakt) iz valeriana officinalis l., radix (odoljenov korijen) (3-6:1); ekstrakcijsko otapalo: etanol 70% v/v, 80 mg ekstrakta (kao suhi ekstrakt) iz passiflora incarnata l., herba (pasiflorova zelen) (5-7:1); ekstrakcijsko otapalo: etanol 50% v/v.